Rafael Holdings Stock Sinks 25% as Niemann-Pick Drug Fails to Meet Main Trial Goal

Shares of Rafael Holdings Inc. (NYSE:RFL) fell sharply in premarket trading on Wednesday, dropping 25% after the company announced its Phase 3 clinical trial for a rare disease treatment failed to meet its primary objective.

Trial Misses Primary Endpoint

The TransportNPC study evaluated the drug Trappsol Cyclo in 94 patients with Niemann-Pick Disease Type C, a rare genetic disorder. According to the company's statement, the trial did not achieve statistical significance on its primary endpoint, which was the change in the 4-domain NPC Clinical Severity Scale at Week 96.

While the drug showed a directionally favorable effect, slowing disease progression by 64% compared to a placebo, the result was not statistically significant, with a p-value of 0.19. A p-value below 0.05 is typically considered the threshold for statistical significance in clinical trials.

Subgroup Analysis Shows Promise

Despite the top-line failure, Rafael Holdings highlighted positive data from a pre-planned subgroup analysis. This analysis focused on 78 patients, or approximately 83% of the study population, who were also receiving background therapy with miglustat and/or leucine.

Ad

Within this specific subgroup, Trappsol Cyclo demonstrated a statistically significant effect:

• It slowed disease progression by 71% compared with the placebo at Week 96.
• The result carried a p-value of 0.046, meeting the threshold for significance.

The company also reported that a separate survival analysis for patients with infantile-onset NPC indicated the treatment was associated with an 85% reduction in the risk of mortality compared to matched external controls. The drug's safety profile was consistent with previous studies, with no new safety signals observed.

Market Impact and Next Steps

The failure to meet the primary endpoint is a significant setback, as it creates a more challenging path to regulatory approval and was the immediate catalyst for the stock's decline. However, based on a previous meeting with the U.S. Food and Drug Administration (FDA), Rafael Holdings stated it remains on track to submit a New Drug Application (NDA) in the fourth quarter of 2026.